论文部分内容阅读
目的观察ＭＶＰ方案治疗非小细胞肺癌（ＮＳＣＬＣ）的治疗效果和毒性反应。方法４５例非小细胞肺癌患者使用ＭＶＰ（ＭＭＣ＋ＶＤＳ＋ＤＤＰ）方案治疗。结果４５例患者中２１例有效，有效率为４６７％。分析诸因素对疗效的影响发现病期早较病期晚疗效好。生活质量评估Ｋａｒｎｏｆｓｋｙ评分升高为６８９％。骨髓抑制为剂量限制性毒性，白细胞下降７５６％无其他严重毒副反应发生。结论ＭＶＰ方案是治疗非小细胞肺癌有效且可以耐受的方案。
Objective To observe the therapeutic effect and toxicity of MVP regimen in the treatment of non-small cell lung cancer (NSCLC). Methods Forty-five NSCLC patients were treated with MVP (MMC+VDS+DDP) regimen. Results Of the 45 patients, 21 were effective and the effective rate was 46.7%. Analysis of the impact of various factors on the efficacy found that the early stage of the disease is better than the disease. The quality of life assessment Karnofsky score increased to 68.9%. Myelosuppression was dose-limiting toxicity, with a 75-6% decrease in white blood cells without any other serious toxicities. Conclusion The MVP regimen is an effective and tolerable regimen for the treatment of non-small cell lung cancer.